SL Parsons

606 total citations
12 papers, 435 citations indexed

About

SL Parsons is a scholar working on Pulmonary and Respiratory Medicine, Hepatology and Surgery. According to data from OpenAlex, SL Parsons has authored 12 papers receiving a total of 435 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Hepatology and 5 papers in Surgery. Recurrent topics in SL Parsons's work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Gastric Cancer Management and Outcomes (4 papers) and Esophageal Cancer Research and Treatment (3 papers). SL Parsons is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Gastric Cancer Management and Outcomes (4 papers) and Esophageal Cancer Research and Treatment (3 papers). SL Parsons collaborates with scholars based in United Kingdom, Germany and France. SL Parsons's co-authors include Abraham Ayantunde, David J. Humes, Jianxiong Tang, J.A. Catton, Pauline Wimberger, E. Schulze, M. M. Heiss, Markus Moehler, S-E. Al-Batran and Barbara Schmalfeldt and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Annals of Oncology.

In The Last Decade

SL Parsons

12 papers receiving 416 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
SL Parsons United Kingdom 6 207 144 96 79 74 12 435
Pedro Villarejo‐Campos Spain 13 274 1.3× 114 0.8× 51 0.5× 97 1.2× 157 2.1× 78 558
Antonio Sommariva Italy 13 360 1.7× 170 1.2× 114 1.2× 108 1.4× 46 0.6× 65 557
Samer A. Naffouje United States 14 305 1.5× 207 1.4× 42 0.4× 178 2.3× 72 1.0× 74 526
Ioannis Kyriazanos Greece 12 247 1.2× 80 0.6× 36 0.4× 142 1.8× 100 1.4× 26 438
T. Genz Germany 10 120 0.6× 167 1.2× 51 0.5× 102 1.3× 88 1.2× 33 528
Mariangela Rutigliani Italy 11 119 0.6× 109 0.8× 21 0.2× 69 0.9× 73 1.0× 31 479
Masashi Miguchi Japan 11 131 0.6× 169 1.2× 14 0.1× 100 1.3× 200 2.7× 53 469
Terri L. Johnson United States 11 157 0.8× 104 0.7× 64 0.7× 63 0.8× 59 0.8× 17 505
Orhan Türken Türkiye 9 70 0.3× 157 1.1× 14 0.1× 65 0.8× 46 0.6× 32 491

Countries citing papers authored by SL Parsons

Since Specialization
Citations

This map shows the geographic impact of SL Parsons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by SL Parsons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites SL Parsons more than expected).

Fields of papers citing papers by SL Parsons

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by SL Parsons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by SL Parsons. The network helps show where SL Parsons may publish in the future.

Co-authorship network of co-authors of SL Parsons

This figure shows the co-authorship network connecting the top 25 collaborators of SL Parsons. A scholar is included among the top collaborators of SL Parsons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with SL Parsons. SL Parsons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Alexandre, Leo, Allan Clark, Michael Lewis, et al.. (2019). Adjuvant statin therapy for oesophageal adenocarcinoma: the STAT-ROC feasibility study. BJS Open. 4(1). 59–70. 6 indexed citations
2.
Reece-Smith, Alexander M., et al.. (2017). Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma. Annals of The Royal College of Surgeons of England. 99(5). 378–384. 2 indexed citations
3.
Tang, Jianxiong, et al.. (2013). Reduction in length of stay for patients undergoing oesophageal and gastric resections with implementation of enhanced recovery packages. Annals of The Royal College of Surgeons of England. 95(5). 323–328. 67 indexed citations
4.
Wimberger, Pauline, Hélène Gilet, M. M. Heiss, et al.. (2012). Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Annals of Oncology. 23(8). 1979–1985. 54 indexed citations
5.
Schmalfeldt, Barbara, Hélène Gilet, Michael Hennig, et al.. (2012). Quality of life in patients with malignant ascites and after treatment with catumaxomab: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Geburtshilfe und Frauenheilkunde. 72(4). 1 indexed citations
6.
Gonschior, A. K., Hélène Gilet, Michael Hennig, et al.. (2011). Quality of Life in Patients With Malignant Ascites and Ascites Symptoms After Treatment With Catumaxomab: Results From a Multicenter Phase II/III Study Comparing Paracentesis Plus Catumaxomab With Paracentesis Alone. mediaTUM (Technical University of Munich). 2 indexed citations
7.
8.
Heiss, M. M., Carsten Bokemeyer, David Arnold, et al.. (2011). The role of relative lymphocyte count as a new biomarker for the effect of catumaxomab on overall survival in patients with malignant ascites: Follow-up results from a phase ll/lll study.. Journal of Clinical Oncology. 29(15_suppl). 2512–2512. 2 indexed citations
9.
10.
Ayantunde, Abraham & SL Parsons. (2007). Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Annals of Oncology. 18(5). 945–949. 282 indexed citations
11.
Parsons, SL, E. Kutarska, P. Koralewski, et al.. (2007). Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/III study. Journal of Clinical Oncology. 25(18_suppl). 5520–5520. 11 indexed citations
12.
Tierney, Gillian, et al.. (1998). A phase II study of the oral matrix metalloproteinase inhibitor, marimastat, in patients with inoperable gastric cancer. Gastroenterology. 114. A688–A688. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pedro Villarejo‐Campos Breakdown of academic impact, for papers by Antonio Sommariva Breakdown of academic impact, for papers by Samer A. Naffouje Breakdown of academic impact, for papers by Ioannis Kyriazanos Breakdown of academic impact, for papers by T. Genz Breakdown of academic impact, for papers by Mariangela Rutigliani Breakdown of academic impact, for papers by Masashi Miguchi Breakdown of academic impact, for papers by Terri L. Johnson Breakdown of academic impact, for papers by Orhan Türken
Rankless by CCL
2026